Almujtama Alraida Medical Co. (9592.SR) — Financial statements
Income statement, balance sheet, and cash flow for Almujtama Alraida Medical Co. — annual and quarterly history with growth and margin analysis.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 455↑5.6% | 431↑5.6% | 408↑11.1% | 367↑20.6% | 304 | |
| Cost of Revenue | 305↑5.7% | 289↑3.6% | 279↑3.0% | 270↑11.3% | 243 | |
| Gross Profit | 150↑5.4% | 142↑10.0% | 129↑33.6% | 97↑56.9% | 62 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00↓100.0% | 7↑45.4% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00↓100.0% | 16↑61.7% | 10 | |
| SG&A Expenses | 139 | 0.00↑100.0% | -279↓1326.9% | 23↑56.6% | 15 | |
| Other Expenses | 0.00↓100.0% | 134↓65.9% | 394↑715.9% | 48↑29.9% | 37 | |
| Operating Expenses | 139↑3.5% | 134↑16.6% | 115↑62.4% | 71↑37.3% | 52 | |
| Total Costs & Expenses | 444↑205.0% | -423↓207.4% | 394↑15.4% | 341↑15.9% | 295 | |
| Operating Results | ||||||
| Operating Income | 11↑15.4% | 9↓33.4% | 14↓45.7% | 26↑158.9% | 10 | |
| Depreciation & Amortization | 0.00↓100.0% | 41↑32.9% | 31↑40.8% | 22↓7.3% | 24 | |
| EBITDA | 11↓81.7% | 59↑16.1% | 51↑5.9% | 48↑38.3% | 35 | |
| EBIT | 11↓38.6% | 17↓10.6% | 20↓23.7% | 26↑134.8% | 11 | |
| Interest & Other Income | ||||||
| Net Interest Income | -9↓0.8% | -9↓51.8% | -6↓0.3% | -6↓53.8% | -4 | |
| Interest Income | 0.00 | 0.00 | 0.00↑100.0% | -2↓20.5% | -1 | |
| Interest Expense | 9↑0.8% | 9↑51.8% | 6↑37.0% | 4↑71.0% | 3 | |
| Non-Operating Income | 0.00↑100.0% | -8↓46.3% | -6↓4654.0% | 0.12↑112.7% | -0.97 | |
| Other Income / Expenses | -2↓92.3% | -1↓118.2% | -0.46↑89.9% | -5↓181.0% | -2 | |
| Income Before Tax | 9↑6.1% | 8↓38.6% | 13↓36.3% | 21↑154.6% | 8 | |
| Income Tax Expense | 0.40↑10.6% | 0.36↓82.8% | 2↓0.1% | 2↑313.5% | 0.51 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 8↑5.9% | 8↓30.4% | 11↓40.3% | 19↑144.3% | 8 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 8↑5.9% | 8↓30.4% | 11↓40.3% | 19↑144.3% | 8 | |
| Bottom-Line Net Income | 8↑5.9% | 8↓30.4% | 11↓40.3% | 19↑144.3% | 8 | |
| EPS (Basic) | 0.88↑6.0% | 0.83↓30.8% | 1.20↓40.3% | 2.01↑145.1% | 0.82 | |
| EPS (Diluted) | 0.88↑6.0% | 0.83↓30.8% | 1.20↓40.3% | 2.01↑145.1% | 0.82 | |
| Weighted Average Shares | 10↓0.2% | 10↑0.6% | 9↓0.1% | 10↑0.0% | 10 | |
| Weighted Average Diluted Shares | 10↓0.2% | 10↑0.6% | 9↓0.1% | 10↑0.0% | 10 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.